Scancell (LON:SCLP) Stock Price Up 20.2% - What's Next?

Scancell Holdings plc (LON:SCLP - Get Free Report) shares were up 20.2% during trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.19 ($0.14). Approximately 1,738,488 shares were traded during trading, an increase of 124% from the average daily volume of 777,450 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Performance

The firm has a market cap of £109.27 million, a price-to-earnings ratio of -16.18 and a beta of 0.35. The firm's 50 day moving average is GBX 8.55 and its 200-day moving average is GBX 10.82. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Scancell (LON:SCLP - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.